Anti-human CD4 induces peripheral tolerance in a human CD4+, murine CD4-, HLA-DR+ advanced transgenic mouse model.
Selection in vivo of potent mAbs to human CD4 useful for immunotherapy, e.g., for the induction of immunological tolerance, is restricted for ethical reasons. We therefore used multiple transgenic mice that lack murine CD4, but express human CD4 specifically on Th cells, and HLA-DR3 as its natural counterligand (CD4/DR3 mice). The injection of CD4/DR3 mice with anti-human CD4 (mAb Max.16H5) before immunization with tetanus toxoid (TT, day 0) totally blocked the formation of specific Abs. This state of unresponsiveness persisted a subsequent boost again performed in the presence of anti-human CD4. When these mice were left untreated for at least 40 days, and were then re-exposed with TT, but in the absence of anti-human CD4, they consistently failed to induce specific Abs (long-term unresponsiveness). Exposure to second party Ags (hen egg lysozyme, human acetylcholine receptor) induced specific Abs comparable with control mice, demonstrating that the anti-CD4-induced unresponsiveness was Ag specific (immunological tolerance). Importantly, the concurrent injection of TT and anti-human CD4 at day 0, followed by another two anti-CD4 treatments, also led to tolerant animals, indicating that tolerance was inducible at the same day as the Ag exposure is provided. We finally demonstrate a limited ability of spleen cells to respond to TT in vitro, indicating that T cells are essentially involved in the maintenance of TT-specific tolerance. These data show for the first time that the human CD4 coreceptor mediates tolerance-inducing signals when triggered by an appropriate ligand in vivo.
Laub
Rüdiger
R
Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Leipzig, Germany. laur@server3.medizin.uni-leipzig.de
Brecht
Rene
R
Dorsch
Martina
M
Valey
Ulrich
U
Wenk
Kerstin
K
Emmrich
Frank
F
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D019138:Antibodies, Blocking / Q000008:administration & dosage / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D015704:CD4 Antigens / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D000939:Epitopes / Q000008:administration & dosage / Q000276:immunology; D015803:HLA-DR3 Antigen / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007108:Immune Tolerance / Q000235:genetics* / Q000276:immunology*; D007274:Injections, Intraperitoneal; D008212:Lymphocyte Depletion; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D023421:Models, Animal; D018448:Models, Immunological; D009113:Muramidase / Q000008:administration & dosage / Q000276:immunology; D011950:Receptors, Cholinergic / Q000008:administration & dosage / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology; D013997:Time Factors; D019076:Transgenes / Q000276:immunology*
D000907:Antibodies, Bacterial; D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D000939:Epitopes; D015803:HLA-DR3 Antigen; D011950:Receptors, Cholinergic; D013745:Tetanus Toxoid; C421864:hen egg lysozyme; D009113:Muramidase